LONDON – Kandy Therapeutics Ltd. is moving to close a £25 million (US$33.5 million) series C round to fund phase IIb development of NT-814, after announcing positive phase Ib/II results for the oral neurokinin (NK) receptor antagonist in the treatment of symptoms of menopause.